In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 John Cleland
Speaker
John Cleland
John Cleland John Cleland

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

Speciality : Chronic Heart Failure

Professor Cleland is a Cardiologist and Director of the Robertson Centre for Biostatistics (Glasgow), an internationally renowned Clinical Trials Unit offering a complete service both to academia and industry for cardiovascular and metabolic disease. His main interest is heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines. Particular current interests include myocardial substrate, congestion & inflammation, telemonitoring & theranostics. He qualified from the University of Glasgow in 1977, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation. He was appointed Prof. at the University of Hull and, in 2013, the National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College London. He founded the European Journal of Heart Failure. He is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure

76 presentations from this speaker

Current and future perspective on heart failure treatment

Event : Webinar 2020

  • Session : HFA Webinars 2020
  • Speaker : J Cleland (Glasgow,GB), JR Teerlink (San Francisco,US), A Coats (Warwickshire,GB)

How do I treat a patient who has recovered his left ventricular ejection fraction?

Event : ESC Congress 2020

  • Session : Challenges in Pharmacotherapy: Heart Failure with mid-Range Ejection Fraction
  • Speaker : J Cleland (Glasgow,GB)

Opening and setting the scene ; Current knowledge and knowledge gaps. What questions will ongoing CVOTs address? Discussion/Questions and Answers.

Event : HFA Discoveries 2020

  • Session : IV iron in heart failure – what we know and what we don’t
  • Speaker : J Cleland (Glasgow,GB), P Kalra (Portsmouth,GB)
  • Sponsored by Pharmacosmos

What have we learned from head-to-head studies of IV iron? Discussion/Questions and Answers.

Event : HFA Discoveries 2020

  • Session : IV iron in heart failure – what we know and what we don’t
  • Speaker : M Wolf (Durham,US), J Cleland (Glasgow,GB)
  • Sponsored by Pharmacosmos

All patients with heart failure and Atrial fibrillation should receive catheter ablation: CONTRA.

Event : Heart Failure 2019

  • Session : The Grand Debate 2: Challenges in heart failure management: mitral regurgitation and atrial fibrillation
  • Speaker : J Cleland (Glasgow,GB)

Cardiac resynchronization therapy: which patients and what are the clinical results?

Event : ESC Congress 2019

  • Session : Heart failure in 2019: latest update on implantable device therapy
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Medtronic

Congestion monitoring.

Event : Heart Failure 2019

  • Session : Parade of devices 1: attend and learn
  • Speaker : J Cleland (Glasgow,GB)

Medical and interventional treatment of atrial fibrillation in heart failure.

Event : ESC Congress 2019

  • Session : Update on novel therapeutic approaches in heart failure
  • Speaker : J Cleland (Glasgow,GB)
  • Heart Failure Association (HFA)

Omecaptiv.

Event : Heart Failure 2019

  • Session : Emerging therapies in heart failure
  • Speaker : J Cleland (Glasgow,GB)
  • Joint Session with the working group on pharmacotherapy of the ESC

Potassium and heart failure.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : S Anker (Berlin,DE), J Cleland (Glasgow,GB), M Lainscak (Murska Sobota,SI), F Zannad (Vandoeuvre,FR)

Role of biomarkers in HFpEF

Event : ESC Congress 2019

  • Session : New hope for HFpEF patients
  • Speaker : J Cleland (Glasgow,GB)

Telecardiology in Heart Failure

Event : ESC Asia 2019

  • Session : What is the Place of Telecardiology in the Modern World
  • Speaker : J Cleland (Glasgow,GB)

Treatment of Functional Mitral Regurgitation - Option Optimal Drug Therapy.

Event : ESC Asia 2019

  • Session : Hot Issues in Valvular Heart Disease
  • Speaker : J Cleland (Glasgow,GB)

Treatment of heart failure – What have we achieved and where are we going?

Event : ESC Congress 2019

  • Session : Chronic heart failure
  • Speaker : J Cleland (Glasgow,GB)
  • Joint with the Cardiological Society of India

We don't always need the defibrillator - Pro.

Event : Heart Failure 2019

  • Session : Hot clinical topics in CRT!
  • Speaker : J Cleland (Glasgow,GB)

Why is it important to treat symptomatic heart failure patients?

Event : ESC Congress 2019

  • Session : Could neuromodulation via the baroreflex work in heart failure after all?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by CVRx Inc

A patient with iron deficiency - What do the guidelines say?

Event : Heart Failure 2018

  • Session : Guidelines in daily practice I - Iron deficiency
  • Speaker : J Cleland (Glasgow,GB)

Case 2: My HF patient post-hospitalization is easy to manage!

Event : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : CS Lam (Singapore,SG), J Cleland (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Coronary revascularisation provides no meaningful clinical benefit over optimal medical therapy in patients with stable ischaemic heart failure - PRO

Event : Heart Failure 2018

  • Session : GRAND DEBATE I - Drugs or interventions - The beat goes on
  • Speaker : J Cleland (Glasgow,GB)

Device therapy in heart failure: a critical appraisal

Event : ESC Congress 2018

  • Session : Heart failure: review, update, and State of the Art in 2018 - Part 2 (Treatment)
  • Speaker : J Cleland (Glasgow,GB)

Devices

Event : Heart Failure 2018

  • Session : The year's best papers on heart failure
  • Speaker : J Cleland (Glasgow,GB)

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Introduction

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Summary and conclusions

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Examining heart failure cases with the experts: challenges faced.

Event : Heart Failure 2018

  • Session : Examining heart failure cases with the experts: challenges faced
  • Speaker : CS Lam (Singapore,SG), M Packer (Dallas,US), J Cleland (Glasgow,GB)
  • Sponsored by Novartis

Heart failure – How to treat in 2018.

Event : ESC Congress 2018

  • Session : Key messages from the most popular ESC webinars
  • Speaker : J Cleland (Glasgow,GB), P Van Der Meer (Groningen,NL)
  • ESC Education committee

ICD and CRT therapy - What is truly evidence-based? Current knowledge

Event : ESC Congress 2018

  • Session : ICD and CRT therapy in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Is there still a role for warfarin ?

Event : Heart Failure 2018

  • Session : Antithrombotics in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Switching between brand name and generic drugs in heart failure. Is it safe ?

Event : ESC Congress 2018

  • Session : Are generic drugs safe in heart failure ?
  • Speaker : J Cleland (Glasgow,GB)

Panel Q&A / Discussion.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : F Zannad (Vandoeuvre,FR), J Cleland (Glasgow,GB), P Van Der Meer (Groningen,NL)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

Patients with non-ischaemic heart failure should receive an ICD - CONTRA.

Event : Heart Failure 2017

  • Session : Implantable Cardioverter Defibrillator (ICD)
  • Speaker : J Cleland (Glasgow,GB)

State of the Art: does steel heal heart failure?

Event : ESC Congress 2017

  • Session : Non-pharmacological treatment of heart failure
  • Speaker : J Cleland (Glasgow,GB)

Targeting heart rate to improve mortality in heart failure with reduced ejection fraction: a comparison of sinus rhythm and atrial fibrillation.

Event : Heart Failure 2017

  • Session : Late Breaking Trials II: Focus on chronic heart failure
  • Speaker : J Cleland (Glasgow,GB)

The path to leadless CRT.

Event : ESC Congress 2017

  • Session : The future therapy of heart failure: shall we find the answers in the crystal ball?
  • Speaker : J Cleland (Glasgow,GB)

The unseen impact of hyperkalemia: implications of suboptimal renin–angiotensin–aldosterone system inhibitor therapy.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : J Cleland (Glasgow,GB)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

What do the Guidelines say about arrhythmias?

Event : Heart Failure 2017

  • Session : Guidelines in Daily Practice V: arrhythmias and devices
  • Speaker : J Cleland (Glasgow,GB)

Who is most likely to benefit from CRT?

Event : Heart Failure 2017

  • Session : Controversies in cardiac resynchronisation therapy
  • Speaker : J Cleland (Glasgow,GB)

Devices and interventions.

Event : Heart Failure 2016

  • Session : Heart Failure 2016 Highlights
  • Speaker : J Cleland (Glasgow,GB)

For whom is CRT best suited - A debate with myself.

Event : Heart Failure 2016

  • Session : New developments and controversial issues in heart failure
  • Speaker : J Cleland (Glasgow,GB)
  • Joint session with the Heart failure Association of India and the CSI-Heart Failure Council

Heart failure and atrial fibrillation: which comes first?

Event : ESC Congress 2016

  • Session : Atrial fibrillation in clinical practice
  • Speaker : J Cleland (Glasgow,GB)

Heart failure with reduced ejection fraction: devices and interventions.

Event : Heart Failure 2016

  • Session : The new ESC Guidelines: Focus on chronic heart failure
  • Speaker : J Cleland (Glasgow,GB)

ICD and CRT.

Event : Heart Failure 2016

  • Session : The new ESC Guidelines: Focus on arrhythmias and devices
  • Speaker : J Cleland (Glasgow,GB)

Indications.

Event : Heart Failure 2016

  • Session : ICD therapy in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Introduction.

Event : Heart Failure 2016

  • Session : Latest developments in cardiac resynchronisation therapy
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Medtronic

LVEF 37% and fully treated, increase heart rate, increased BNP, and QRS of 141ms - What to do? What do the Guidelines say?

Event : ESC Congress 2016

  • Session : Common difficult decisions in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Management of chronic heart failure devices and interventions

Event : ESC Congress 2016

  • Session : The new ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  • Speaker : J Cleland (Glasgow,GB)

Non-invasive monitoring of congestion

Event : ESC Congress 2016

  • Session : What's new in chronic heart failure devices
  • Speaker : J Cleland (Glasgow,GB)

Oral anticoagulants today.

Event : Heart Failure 2016

  • Session : Oral anticoagulation in patients with heart failure: today and tomorrow
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Bayer

QRS width and bundle branch morphology.

Event : Heart Failure 2016

  • Session : Controversies in cardiac re-synchronisation therapy
  • Speaker : J Cleland (Glasgow,GB)
  • Joint Session with the European Heart Rhythm Association (EHRA)

ARNIs (LCZ696). Ready for prime time - CONTRA.

Event : Heart Failure 2015

  • Session : Hot issues in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Cardiac myosin activators.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : J Cleland (Glasgow,GB)

Clinical development concepts moving forward.

Event : Heart Failure 2015

  • Session : Mitochondria in heart failure: a new target for therapy and recent first results
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Charité University Berlin and Stealth Peptides

CRT and ICD.

Event : ESC Congress 2015

  • Session : Devices for heart failure today
  • Speaker : J Cleland (Glasgow,GB)

Discussion: An implantable haemodynamic monitor for long term wireless monitoring of left heart function - first in human study.

Event : Heart Failure 2015

  • Session : Late Breaking Trials II: Heart failure management
  • Speaker : J Cleland (Glasgow,GB)

Drug therapy. A tale of statins and antithrombotics.

Event : Heart Failure 2015

  • Session : Should we manage the patient with ischemic cardiomyopathy differently?
  • Speaker : J Cleland (Glasgow,GB)

Iron deficiency - a common neglected burden in heart failure clinical management and its diagnosis.

Event : Heart Failure 2015

  • Session : Changing conventions – Intravenous iron in heart failure
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Monitoring devices in heart failure

Event : EHRA 2015

  • Session : New devices for heart failure - when, which device and in whom
  • Speaker : J Cleland (Glasgow,GB)

Non invasive hemodynamic monitoring.

Event : Acute Cardiovascular Care 2015

  • Session : Diagnostic tools in the management of acute heart failure
  • Speaker : J Cleland (Glasgow,GB)

Non-LBBB with QRS >150 ms.

Event : EHRA 2015

  • Session : Cardiac resynchronisation therapy (CRT) in heart failure: indication or not?
  • Speaker : J Cleland (Glasgow,GB)

Oral anticoagulation in patients with heart failure: today and tomorrow.

Event : Heart Failure 2015

  • Session : Novel oral anticoagulant use in patients with heart failure: present and future perspectives
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Bayer Healthcare

Panel discussion - Changing conventions - Intravenous iron in heart failure.

Event : ESC Congress 2015

  • Session : Changing conventions - Intravenous iron in heart failure
  • Speaker : S Anker (Berlin,DE), P Ponikowski (Wroclaw,PL), G Filippatos (Athens,GR), J Cleland (Glasgow,GB)
  • Sponsored by Charité

Selection of CRT candidates: Which patients benefit most?

Event : EHRA 2015

  • Session : Improving CRT response: Patient selection, implantation and therapy
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Medtronic

The pharmacological approach.

Event : Acute Cardiovascular Care 2015

  • Session : End-stage heart failure
  • Speaker : J Cleland (Glasgow,GB)

Are the guidelines appropriate to avoid non responders?

Event : ESC Congress 2014

  • Session : Enhancing cardiac resynchronisation therapy response
  • Speaker : J Cleland (Glasgow,GB)

Is clinical assessment and ECG enough?

Event : ESC Congress 2014

  • Session : How to pre-select responders to cardiac resynchronisation therapy?
  • Speaker : J Cleland (Glasgow,GB)

MORE-CRT: Discussant review

Event : ESC Congress 2014

  • Session : Hot Line: Cardiovascular disease: novel therapies
  • Speaker : J Cleland (Glasgow,GB)

Telehealth - good value for money?

Event : ESC Congress 2014

  • Session : Technology and the Internet: innovative ways to provide cardiovascular disease prevention
  • Speaker : J Cleland (Glasgow,GB)

Cardiac pacing and cardiac resynchronisation therapy: questions and answers to the panellists.

Event : ESC Congress 2013

  • Session : Meet the Guidelines Task Force I
  • Speaker : M Brignole (Lavagna,IT), J Cleland (Glasgow,GB)

New drugs.

Event : ESC Congress 2013

  • Session : Treating acute and advanced heart failure: what clinicians need to know in 2013
  • Speaker : J Cleland (Glasgow,GB)

New kids.

Event : ESC Congress 2013

  • Session : Antithrombotics in heart failure
  • Speaker : J Cleland (Glasgow,GB)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are